Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retroperitoneal Neoplasms | 28 | 2023 | 329 | 6.540 |
Why?
|
| Sarcoma | 31 | 2023 | 1786 | 4.360 |
Why?
|
| Soft Tissue Neoplasms | 12 | 2023 | 1151 | 2.960 |
Why?
|
| Liposarcoma | 9 | 2023 | 283 | 2.490 |
Why?
|
| Gastrointestinal Stromal Tumors | 6 | 2022 | 615 | 1.460 |
Why?
|
| Leiomyosarcoma | 3 | 2023 | 424 | 1.100 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2018 | 951 | 1.070 |
Why?
|
| Neoplasm Recurrence, Local | 20 | 2023 | 9274 | 1.010 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2023 | 60 | 0.880 |
Why?
|
| Nephrectomy | 3 | 2022 | 1017 | 0.750 |
Why?
|
| Stomach Neoplasms | 5 | 2022 | 1423 | 0.610 |
Why?
|
| Videoconferencing | 1 | 2020 | 203 | 0.600 |
Why?
|
| Adrenal Glands | 1 | 2017 | 556 | 0.490 |
Why?
|
| Hepatectomy | 2 | 2022 | 560 | 0.480 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2016 | 184 | 0.480 |
Why?
|
| Interviews as Topic | 1 | 2020 | 2656 | 0.420 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2014 | 321 | 0.420 |
Why?
|
| Combined Modality Therapy | 6 | 2020 | 8551 | 0.420 |
Why?
|
| Laparoscopy | 2 | 2021 | 2155 | 0.390 |
Why?
|
| Extremities | 3 | 2022 | 867 | 0.390 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 1118 | 0.380 |
Why?
|
| Iodine Radioisotopes | 1 | 2014 | 1032 | 0.370 |
Why?
|
| Antineoplastic Agents | 6 | 2022 | 13629 | 0.370 |
Why?
|
| Nomograms | 4 | 2023 | 238 | 0.370 |
Why?
|
| Neuroendocrine Tumors | 1 | 2017 | 649 | 0.360 |
Why?
|
| Strongyloidiasis | 1 | 2010 | 27 | 0.350 |
Why?
|
| Jejunal Diseases | 1 | 2010 | 46 | 0.350 |
Why?
|
| Pancreatectomy | 4 | 2022 | 809 | 0.340 |
Why?
|
| Duodenal Diseases | 1 | 2010 | 99 | 0.340 |
Why?
|
| Colon | 1 | 2017 | 1788 | 0.330 |
Why?
|
| Schistosomiasis mansoni | 1 | 2010 | 94 | 0.330 |
Why?
|
| Diverticulum | 1 | 2010 | 137 | 0.320 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 4317 | 0.320 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2018 | 2415 | 0.320 |
Why?
|
| Neoadjuvant Therapy | 4 | 2022 | 2811 | 0.300 |
Why?
|
| Solitary Fibrous Tumors | 2 | 2020 | 67 | 0.300 |
Why?
|
| Retrospective Studies | 27 | 2023 | 80301 | 0.290 |
Why?
|
| Survival Rate | 12 | 2021 | 12806 | 0.290 |
Why?
|
| Brachytherapy | 1 | 2014 | 1240 | 0.280 |
Why?
|
| Retroperitoneal Space | 3 | 2022 | 173 | 0.270 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 6310 | 0.260 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2020 | 506 | 0.260 |
Why?
|
| Morbidity | 6 | 2022 | 1765 | 0.260 |
Why?
|
| Sulfonamides | 1 | 2014 | 1973 | 0.240 |
Why?
|
| Pyrazoles | 1 | 2014 | 1992 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 3618 | 0.230 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 4312 | 0.220 |
Why?
|
| Catheter Ablation | 1 | 2017 | 2755 | 0.220 |
Why?
|
| Wound Healing | 1 | 2014 | 2786 | 0.220 |
Why?
|
| Lymph Node Excision | 2 | 2020 | 1305 | 0.220 |
Why?
|
| Humans | 59 | 2023 | 760261 | 0.220 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 1130 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3086 | 0.210 |
Why?
|
| Ganglioneuroma | 1 | 2022 | 53 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3206 | 0.200 |
Why?
|
| Kidney | 1 | 2017 | 7072 | 0.200 |
Why?
|
| Postoperative Complications | 5 | 2022 | 15680 | 0.200 |
Why?
|
| Neoplasm Metastasis | 5 | 2018 | 4891 | 0.190 |
Why?
|
| Pandemics | 1 | 2020 | 8621 | 0.170 |
Why?
|
| Prognosis | 8 | 2023 | 29636 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 3 | 2022 | 5333 | 0.170 |
Why?
|
| Renal Replacement Therapy | 1 | 2022 | 281 | 0.170 |
Why?
|
| Radiotherapy | 2 | 2017 | 1505 | 0.170 |
Why?
|
| Middle Aged | 25 | 2022 | 220175 | 0.160 |
Why?
|
| Bone Neoplasms | 2 | 2021 | 2532 | 0.160 |
Why?
|
| Personnel Selection | 1 | 2020 | 193 | 0.150 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 39254 | 0.150 |
Why?
|
| Neoplasm Staging | 6 | 2022 | 11141 | 0.150 |
Why?
|
| Aged | 19 | 2022 | 168995 | 0.140 |
Why?
|
| Splenectomy | 1 | 2018 | 391 | 0.140 |
Why?
|
| Disease Management | 2 | 2017 | 2508 | 0.130 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 2214 | 0.130 |
Why?
|
| Adrenalectomy | 1 | 2017 | 348 | 0.130 |
Why?
|
| SEER Program | 2 | 2018 | 1532 | 0.130 |
Why?
|
| Gastrectomy | 2 | 2021 | 677 | 0.120 |
Why?
|
| Hemangiosarcoma | 1 | 2017 | 218 | 0.120 |
Why?
|
| Neuroblastoma | 1 | 2022 | 1252 | 0.110 |
Why?
|
| Adult | 16 | 2023 | 219847 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2020 | 10185 | 0.110 |
Why?
|
| Female | 25 | 2022 | 391011 | 0.110 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 21065 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 2178 | 0.110 |
Why?
|
| Male | 25 | 2022 | 359413 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 3531 | 0.110 |
Why?
|
| Biological Products | 1 | 2022 | 914 | 0.110 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2017 | 549 | 0.110 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 58947 | 0.100 |
Why?
|
| Colectomy | 1 | 2017 | 694 | 0.100 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 6855 | 0.100 |
Why?
|
| Faculty, Medical | 1 | 2020 | 1192 | 0.100 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 3381 | 0.100 |
Why?
|
| Lymph Nodes | 2 | 2022 | 3491 | 0.100 |
Why?
|
| Age Factors | 4 | 2022 | 18415 | 0.090 |
Why?
|
| Endosonography | 1 | 2015 | 604 | 0.090 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 5797 | 0.090 |
Why?
|
| Strongyloides stercoralis | 1 | 2010 | 23 | 0.090 |
Why?
|
| Veterans Health | 2 | 2022 | 216 | 0.090 |
Why?
|
| Length of Stay | 2 | 2021 | 6472 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2021 | 1819 | 0.090 |
Why?
|
| Safety | 1 | 2014 | 1149 | 0.090 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 938 | 0.080 |
Why?
|
| Preoperative Care | 2 | 2015 | 2255 | 0.080 |
Why?
|
| Disease-Free Survival | 4 | 2023 | 6830 | 0.080 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2014 | 576 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2019 | 1790 | 0.080 |
Why?
|
| Urinary Bladder | 1 | 2015 | 1166 | 0.080 |
Why?
|
| Carcinoma | 1 | 2020 | 2334 | 0.080 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2015 | 796 | 0.080 |
Why?
|
| Veterans | 1 | 2022 | 2640 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 1 | 2014 | 1335 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 2296 | 0.070 |
Why?
|
| Biopsy | 1 | 2019 | 6775 | 0.070 |
Why?
|
| Risk Factors | 5 | 2022 | 74269 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 1189 | 0.070 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 1726 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 1919 | 0.060 |
Why?
|
| Propensity Score | 2 | 2020 | 1918 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 20484 | 0.050 |
Why?
|
| Registries | 1 | 2018 | 8449 | 0.050 |
Why?
|
| Incidence | 2 | 2017 | 21378 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2021 | 54263 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2022 | 12532 | 0.050 |
Why?
|
| Melanoma | 1 | 2019 | 5695 | 0.040 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2020 | 25 | 0.040 |
Why?
|
| Europe | 2 | 2018 | 3433 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2020 | 161 | 0.040 |
Why?
|
| Pancreatic Fistula | 1 | 2021 | 148 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2021 | 64947 | 0.040 |
Why?
|
| Medicare | 1 | 2018 | 6771 | 0.040 |
Why?
|
| Cancer Care Facilities | 1 | 2022 | 425 | 0.040 |
Why?
|
| Young Adult | 4 | 2021 | 58673 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2014 | 10434 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 36247 | 0.040 |
Why?
|
| Hospitals | 2 | 2022 | 3929 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2022 | 727 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2022 | 7803 | 0.040 |
Why?
|
| Adolescent | 4 | 2021 | 87747 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1723 | 0.040 |
Why?
|
| Axilla | 1 | 2019 | 618 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 22025 | 0.030 |
Why?
|
| United States | 3 | 2020 | 72363 | 0.030 |
Why?
|
| London | 1 | 2016 | 234 | 0.030 |
Why?
|
| Poland | 1 | 2016 | 196 | 0.030 |
Why?
|
| Pancreas | 1 | 2022 | 1677 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 1122 | 0.030 |
Why?
|
| Ontario | 1 | 2016 | 405 | 0.030 |
Why?
|
| Disease Progression | 2 | 2022 | 13505 | 0.030 |
Why?
|
| China | 1 | 2020 | 2340 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2020 | 1207 | 0.030 |
Why?
|
| Germany | 1 | 2016 | 875 | 0.030 |
Why?
|
| Rupture | 1 | 2015 | 443 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 12156 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 1821 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2019 | 8018 | 0.030 |
Why?
|
| Canada | 1 | 2018 | 2128 | 0.030 |
Why?
|
| North America | 1 | 2016 | 1282 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 965 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2020 | 6242 | 0.020 |
Why?
|
| Consensus | 1 | 2021 | 3106 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 2852 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 2945 | 0.020 |
Why?
|
| Netherlands | 1 | 2016 | 2213 | 0.020 |
Why?
|
| Animals | 2 | 2014 | 167940 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2016 | 2932 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2016 | 1897 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2015 | 814 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 2897 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6545 | 0.020 |
Why?
|
| Sex Factors | 1 | 2021 | 10530 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2019 | 24086 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 11064 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 2880 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 7268 | 0.020 |
Why?
|
| Boston | 1 | 2016 | 9282 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 4012 | 0.010 |
Why?
|
| Contrast Media | 1 | 2015 | 5301 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 5640 | 0.010 |
Why?
|
Concepts
(177)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(42)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_